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Rheumatoid synovial fibroblasts
differentiate into distinct subsets in the
presence of cytokines and cartilage
Adam P. Croft1†, Amy J. Naylor1†, Jennifer L. Marshall1, Debbie L. Hardie1, Birgit Zimmermann2, Jason Turner1,
Guillaume Desanti1, Holly Adams1, Adrian I. Yemm1, Ulf Müller-Ladner2, Jean-Michel Dayer3, Elena Neumann2,
Andrew Filer1,4 and Christopher D. Buckley1,5*
Abstract
Background: We investigated two distinct synovial fibroblast populations that were located preferentially in the
lining or sub-lining layers and defined by their expression of either podoplanin (PDPN) or CD248, and explored
their ability to undergo self-assembly and transmigration in vivo.
Methods: Synovial fibroblasts (SF) were cultured in vitro and phenotypic changes following stimulation with
interleukin (IL)-1β, tumor necrosis factor (TNF)-α, and transforming growth factor (TGF)-β1 were examined. To
examine the phenotype of SF in vivo, a severe combined immunodeficiency (SCID) human-mouse model of
cartilage destruction was utilised.
Results: SF in the lining layer in rheumatoid arthritis (RA) expressed high levels of PDPN compared to the normal
synovium, whereas CD248 expression was restricted to sub-lining layer cells. TNF-α or IL1 stimulation in vitro
resulted in an increased expression of PDPN. In contrast, stimulation with TGF-β1 induced CD248 expression. In the
SCID human-mouse model, rheumatoid SF recapitulated the expression of PDPN and CD248. Fibroblasts adjacent
to cartilage expressed PDPN, and attached to, invaded, and degraded cartilage. PDPN+ CD248– SF preceded the
appearance of PDPN– CD248+ cells in contralateral implants.
Conclusions: We have identified two distinct SF populations identified by expression of either PDPN or CD248
which are located within different anatomical compartments of the inflamed synovial membrane. These markers
discriminate between SF subsets with distinct biological properties. As PDPN-expressing cells are associated with
early fibroblast migration and cartilage erosion in vivo, we propose that PDPN-expressing cells may be an attractive
therapeutic target in RA.
Background
Rheumatoid arthritis (RA) is characterised by the forma-
tion of a hyperplastic and invasive synovium, comprised
of an expanded synovial fibroblast population with infil-
tration of inflammatory cells [1]. Synovial fibroblasts
(SF) are key mediators of joint destruction and disease
persistence [2, 3]. Despite their fundamental importance,
these cells have yet to be directly targeted therapeutic-
ally, in part due to a lack of cell-specific markers and a
full understanding of their biology and role in the patho-
genesis of RA [4].
Fibroblasts within the synovium are a heterogeneous
cell population with distinct anatomical and functional
phenotypes [1]. During persistent synovial inflammation,
SF undergo epigenetic changes, assume a stable, acti-
vated phenotype, and are capable of invading and
destroying articular cartilage [1, 5]. Rheumatoid but not
normal SF are also capable of vascular transmigration
from their site of primary origin to distant cartilage sites
where they attach and invade cartilage [6, 7].
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Using an unbiased screen with a panel of monoclonal
antibodies to fibroblast cell surface proteins, we have
previously identified two trans-membrane proteins
(CD248 and GP38) that are highly expressed in inflamed
tissue in both mice and humans [4, 8–11]. The differen-
tial expression of these fibroblast cell surface markers
lead us to propose that specific subsets of fibroblasts, ex-
pressing these markers, may play an important and dis-
cordant role in the persistence of inflammation and
cartilage erosion in RA [12, 13].
In this study, we demonstrate that CD248 and podo-
planin (PDPN) identify distinct subsets of SF. Both
markers and their related functions are induced tem-
porarily by cytokine treatment in vitro. Furthermore,
re-implantation of these subsets of SF in vivo results
in recapitulation of many of their functional properties in-
cluding anatomical location and ability to invade cartilage.
Methods
Patients, human synovium, and cartilage
The clinical features of the patients who donated sam-
ples are summarized in Table 1. Synovial tissue was ob-
tained from patients with established RA and healthy
individuals by ultrasound-guided synovial biopsy as pre-
viously described [14]. Cartilage tissue was obtained
from healthy areas of cartilage in patients undergoing
joint replacement surgery for osteoarthritis. All patients
with RA fulfilled the 1987 revised American College of
Rheumatology Criteria for RA. Tissue was snap frozen
in liquid nitrogen and 5-μm sections were cut prior to
fixation in 4 °C acetone.
Isolation of fibroblast lines and cell culture
All tissue culture reagents were purchased from Sigma
(St. Louis, MO, USA) unless stated otherwise. Fibro-
blasts were isolated from synovial tissue as previously
described [15]. In brief, tissue samples were minced
under sterile conditions and dissociated for 2 h at 4 °C
with vigorous shaking. The resulting cell/tissue mixture
was washed in fresh medium and cultured until adher-
ent fibroblast colonies became confluent. Fibroblasts
were cultured in RPMI 1640 supplemented with 1 mM
sodium pyruvate, 1 % nonessential amino acid solution,
10 mM glutamine, 100 U/ml penicillin, 100 g/ml
streptomycin, and 10 % fetal calf serum (FCS) incubated
at 37 °C and 5 % CO2. All experiments were performed
with at least five sets of matched primary fibroblast lines
between passages 2 and 6. For cytokine stimulation assays,
primary SF were seeded in triplicates in six-well plates
(100,000 cells/well) and incubated until confluence. The
cells were serum-starved in RPMI media supplemented
with 2 % heat- inactivated FCS for 6 h prior to the
addition of human recombinant cytokines (all from
Peprotech, Rocky Hill, USA). Tumor necrosis factor
(TNF)-α (10 ng/ml), interleukin (IL)-1β (1 ng/ml), and
transforming growth factor (TGF)-β1 (10 ng/ml) were
added in low-serum media. The cells were harvested by
treatment with acutase after 24, 48 and 72 hours and ex-
pression of phenotypic markers were analysed.
Antibodies and immunoflorescence microscopy
Immunostaining and confocal microscopy were per-
formed as previously described [16–18]. We used a
species-specific antiCD248 antibody that has been exten-
sively characterized [11, 18–21]. B1/35 is an IgG1 mouse
antihuman monoclonal that specifically recognizes hu-
man CD248 and does not crossreact with mouse tissue
[11, 20, 21]. The monoclonal antiPDPN (eBioscience
clone NZ 3.1; Hatfield, UK) was used for flow cytometry
and was directly conjugated to PE, and purified for im-
munostaining. Antihuman VCAM-1 (mouse, IgG1),
CD68 (mouse, IgG1 kappa), and CD90 (mouse IgG1
kappa) were obtained from eBioscience. Isotype controls
were obtained from eBioscience and Dako (Ely, UK).
Antimouse IgG1-FITC, antimouse IgG2b Cy5, anti-
mouse IgG2a Alexa-555 (all Southern Biotech,
Table 1 Demographics of patient samples
Rheumatoid arthritis (n = 20) Non-inflammatory controls (n = 7) Significance
Age (years) 56 (48–64) 58 (46-69) ns
Female, n (%) 9 (45) 3 (42.9) ns
ESR (mm/h) 46.5 (21–62.5) –
CRP (mg/l) 26 (7.5–44.5) –
DAS28ESR 5.52 (4.47–6.67) –
Symptom duration (weeks) 9 (4.3–36) –
IgM-RF positive, n (%) 9 (45) –
ACPA positive, n (%) 12 (60) –
RhF and ACPA both positive, n (%) 9 (45) –
Values are shown as median (interquartile range), except where stated
ACPA anti-citrullinated protein antibody, CRP C-reactive protein, DAS28ESR Disease Activity Score-28 with erythrocyte sedimentation rate (ESR), IgM-RF immunoglobulin
M-rheumatoid factor, ns not significant, RhF rheumatoid factor
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Birmingham, AL, USA), antirabbit-Alexa 633, and
antiFITC-Alexa 488 (Life Technologies, Paisley, UK)
were used as secondary and tertiary reagents. Tissue sec-
tions from severe combined immunodeficiency (SCID)
mice were analyzed for invasion as previously described
[6, 7, 22]. Species-specific antibodies were used to identify
human cells and exclude staining of mouse fibroblasts in
the tissue sections. Cellular density and cell counts were
performed on tile scans at × 10 magnification to include
an assessment of all cells. High-magnification imaging
(×40) was used to confirm the identify of cells and to
analyze the anatomical distribution of cells. The Image J
“cell counter” plugin (available at http://rsbweb.nih.gov/ij/
plugins/cell-counter.html) was used for cell count analysis
(Rasband WS, ImageJ, US National Institutes of Health,
Bethesda, Maryland, USA; http://imagej.nih.gov/ij/,
1997–2014).
Images were acquired from one to eight different re-
gions of each tissue section using a Zeiss LSM 510 con-
focal scanning microscope and ZEN pro 2011 imaging
software (Zeiss, Welwyn Garden City, UK). Settings
within one staining experiment remained unchanged.
For each image, the number of pixels with intensity from
30 to 255 of every fluorescent channel was quantified
with ZEN pro 2011 and divided by a manually defined
area (μm2) only including tissue zones containing cells.
The average number of fluorescent pixels with intensity
30–255 per unit area (pixel/UA) from all images within
one synovial tissue section was calculated. In addition,
two researchers independently assessed the fluorescence
level of every marker using a semiquantitative scoring
system of grade 0–4 combining staining intensity and
number of positive cells. Semiquantitative scores corre-
lated well with unbiased pixel analysis scores (Spearman’s
rho >0.7, p < 0.001 for all markers; data not shown).
In order to measure and account for any variation be-
tween staining of sections during different staining runs,
we stained sections from the same patients on each oc-
casion for CD248 and PDPN. Intraclass correlation coef-
ficients (ICC) for CD248 (ICC 0.69) and PDPN (ICC
0.74) reflected good (ICC >0.7) internal consistency.
For immunofluorescence of fibroblast lines, cells from
synovial biopsy tissue were seeded onto chamber slides
at passage 3 with 3 × 104 cells per well and left for 48 h
prior to fixation in acetone for 20 min at 4 °C. Slides
were subsequently stored at –80 °C until use. Slides were
blocked with 10 % normal goat serum and stained using
antibodies as described above. Images were acquired on
the Leica DM6000 using Leica Application Suite Ad-
vanced Fluorescence (Leica Camera AG, Germany).
Flow cytometry
Primary SF cell cultures from patients with RA (n = 5)
were washed with phosphate-buffered saline (PBS) and
treated with accutase (Life Technologies) dissociation
buffer. Cells were stained with APC-conjugated antihu-
man CD90 (eBioscience), PE conjugated antihuman
PDPN (eBioscience, clone NZ-1.3), and FITC conjugated
antihuman CD248 B1/35 (produced in house). Isotype
controls (eBioscience) were used to set the gates for
positive and negative populations. Fluorescence was
measured using the FACSCanto II system (BD Biosci-
ences, Oxford, UK) equipped with DIVA 6.2 software
(BD Biosciences), and data were analyzed using FlowJo
8.7.3 software (Tree Star Inc., Ashland, OR, USA).
Quantitative real-time reverse transcription polymerase
chain reaction (RT-PCR)
Cell pellets were assayed by real-time PCR for mRNA
expression using TaqMan gene expression assays for
human CD248 (Hs.00535586), human PDPN
(Hs00366766_m1), and human 18S (Hs.03928985) (Life
Technologies). Samples were reverse transcribed using a
Cells-to-cDNA kitorkit or TaqMan Reverse Transcrip-
tion kit (both Life Technologies) with PCR Master Mix
and TaqMan Universal Master Mix II reagent (Life
Technologies). Assays were run on a 7900HT Real-Time
PCR system (Life Technologies) according to the manu-
facturer’s protocol. Data were obtained as Ct values. Ex-
pression values for the gene of interest were normalized
to those for 18S ribosomal RNA and were transformed
to assume a doubling of product with each PCR cycle,
calculated using the comparative threshold cycle (Ct)
method and then 2–delta Ct formula, as the Ct gene of
interest minus the Ct housekeeping gene. Results were
expressed as the fold-change relative to values in the
control, untreated samples. Each experiment was per-
formed in duplicate and repeated in five different primary
RA synovial fibroblast donor cell lines.
SCID mouse model of cartilage destruction
Mice used in this study were housed in individually ven-
tilated cages in groups of 3–6 individuals on a 12-h
light-dark cycle. Healthy areas from human cartilage
were obtained from patients undergoing joint replace-
ment surgery due to osteoarthritis. Rheumatoid arthritis
synovial fibroblasts (RASFs) from passage 4–5 were
trypsinized and added to pieces of a sterile inert gel
sponge (3–4 mm3) at a concentration of 1 × 105 cells/
sponge. The sponges and pieces of cartilage (1–2 mm3)
were implanted under the adipose capsule of the kidney
or subcutaneously in 4-week-old female SCID mice
(Charles River, Harlow, UK). For migration assays a
cartilage/sponge-only matrix was implanted on the
contralateral side simultaneously. Implants and blood
were collected at the indicated time points. Implants
were frozen prior to tissue sections (10-μm or 8-μm) being
obtained, fixed in acetone, and stained with hematoxylin
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and eosin. Invasion of RASFs into cartilage was evaluated
by a minimum of two observers, who were blinded to the
source of the implants, using a semiquantitative five-point
scale as described previously [8]. For confocal microscopy
and quantification, eight tissue sections were analysed
per time point in three independent experiments
using three mice.
Results
CD248 and PDPN identify distinct fibroblast subsets
within the hyperplastic inflamed human synovium
We first examined the expression of CD248 and PDPN
in resting and inflamed synovium using tissue sections
of human synovial membrane isolated from healthy indi-
viduals and patients with established RA. The expression
of PDPN but not CD248 was significantly upregulated in
inflamed compared to healthy synovial tissue (Fig. 1a
and b). In inflamed tissue, PDPN was mainly expressed
by SF in the lining layer whereas CD248 was predomin-
antly expressed by fibroblasts in the sub-lining layer
(Fig. 1a). Some PDPN cells could be seen in the sub-
lining layer and likely represent lymphatic endothelial
cells or perivascular fibroblasts. High-magnification con-
focal images of rheumatoid synovium in the lining ver-
sus sub-lining layer confirmed that CD248 expression
was found in association with other known sub-lining
layer markers such as CD90, while PDPN expression
was found in association with the lining layer markers
vascular cell adhesion molecule (VCAM)-1 and protein
disulfide isomerase (PDI) (Fig. 1c). Some CD68-positive
cells in the lining layer were also PDPN-positive and
these cells of monocyte-macrophage lineage have been
described previously in mice [23].
Synovial fibroblasts show phenotypic plasticity
Using SF from rheumatoid synovial biopsy tissue ex-
plants, we next evaluated the expression of PDPN and
CD248 in cultured SF using immunofluorescence mi-
croscopy. SF in culture were heterogeneous with respect
to the expression of PDPN and CD248 (Fig. 2). There
were distinct populations of PDPN- and CD248-
expressing fibroblasts and only very rarely were cells
seen that stained positive for both markers.
To evaluate whether the phenotypic markers observed
in vivo were inducible in vitro, SF were cultured in low
serum conditions (2 % FCS) with TGF-β1, TNF-α, or IL-1β
. These cytokines were chosen as TNF-α and IL-1β have
been shown to stimulate fibroblasts to produce large
amounts of proteolytic enzymes that are destructive to car-
tilage and bone [2]. TGF-β1 is also known to be capable of
inhibiting the synthesis of metalloproteinases and thereby
to inhibit joint damage [2].
Expression of PDPN and CD248 in stimulated SF was
assessed using RT-PCR for RNA expression (Fig. 3) and
flow cytometry (Fig. 4) for protein cell surface expres-
sion. RASF stimulated with either TNF-α or IL-1β up-
regulated the expression of PDPN at both the mRNA
and protein level over 72 h of exposure. In contrast, this
treatment did not result in an upregulation of CD248
expression but rather significantly reduced CD248 ex-
pression. Stimulation with TGF-β1 resulted in increased
expression of CD248 but not PDPN expression at both
the protein and mRNA levels. Following seeding at equal
Fig. 1 PDPN and CD248 markers identify specific fibroblast subsets localized to distinct anatomical compartments in the inflammatory synovium.
a Representative confocal images of synovial biopsy tissue from healthy and rheumatoid arthritis (RA) synovium. Expression of podoplanin (PDPN)
and CD248 is shown in healthy (normal) compared to rheumatoid synovium. b Quantification of marker expression in synovial tissue of patients
with RA compared to normal controls. Data are expressed as median and interquartile range for CD248 (p = 0.65 by Mann-Whitney U test; n = 7
normal; n = 19 RA) and for PDPN (*p = 0.0013 by Mann-Whitney U test; n = 7 normal; n = 20 RA). c High magnification confocal images of rheumatoid
synovium showing the lining (R1) versus sub-lining (R2) layer interface and expression of cell surface markers. Scale bars= 100 μm. PDI protein disulfide
isomerase, UA unit area, VCAM-1 vascular adhesion molecule-1
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plating density, there was no significant difference in the
proliferation rate of the two cell populations after 72 h.
Continuous cytokine stimulation was required to main-
tain the expression of these cell surface markers since
removal of cytokines at 72 h resulted in a return to the
baseline expression of both PDPN and CD248 when
evaluated at 24 h post-removal (Fig. 4b).
Rheumatoid SF self-organize into lining and sub-lining
layers in the presence of human cartilage
We next explored whether PDPN-expressing fibroblasts
could invade articular cartilage in vivo using the SCID
mouse model of cartilage destruction [5, 6, 24]. RASF
were seeded into an inert sponge and co-implanted with
Fig. 3 Cytokines stimulate differential expression of CD248 and podoplanin (PDPN) in vitro. Expression of PDPN and CD248 by quantitative RT-PCR
expressed as mRNA fold-change from unstimulated cells (mean ± SEM). **P < 0.01 by one-way ANOVA with Bonferroni post hoc analysis. IL interleukin,
TGF transforming growth factor, TNF tumor necrosis factor
Fig. 2 Expression of CD248 and podoplanin (PDPN) in cultured
RASF. Three representative confocal images of different RASF lines in
culture are shown, ×40 magnification: green, CD248; blue, PDI; red
PDPN; and grey, nuclei. PDI protein disulfide isomerase
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Fig. 4 (See legend on next page.)
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healthy human articular cartilage subcutaneously or
under the renal capsule of SCID mice. At 60 days post-
implantation, in the presence of cartilage alone, RASF
self-assembled with a cellular architecture that recapitu-
lated the organization of PDPN and CD248 observed in
the inflamed human synovium (Fig. 5a). Fibroblasts
proximate to the cartilage (less than 20 μm distance)
were PDPN+ CD248– and cells beneath this layer
(greater than 20 μm from the cartilage) expressed
CD248 and rarely expressed PDPN (Fig. 5b) CD248+
cells formed an apparent sub-lining layer beneath the
layer of PDPN-expressing fibroblasts. SF that had in-
vaded cartilage did not express CD248 but rather
expressed PDPN. This occurred despite the fact that the
fibroblasts originated from a heterogeneous mix of
CD248- and PDPN-expressing RASF (Fig. 2).
Recent studies using the SCID mouse model have
shown that SF can migrate from the primary site of im-
plantation to distant sites of exposed cartilage through
the vascular system [6]. To analyze whether PDPN+ or
CD248+ fibroblasts were involved in this process, a sec-
ondary implant containing cartilage and sponge only was
implanted either subcutaneously or under the renal cap-
sule on the contralateral side to the primary fibroblast-
containing implant. At 60 days post-implantation there
was no significant difference in the invasion score of fibro-
blasts into cartilage between the primary and secondary
implant (2.3 ± 0.9 in the primary implant and 1.8 ± 0.7 in
the secondary implant; p = 0.56 by Student’s t test). There
was also no significant difference in the organization of
RASF into PDPN+ and CD248+ cells or the percentage of
cells expressing each of these markers between the pri-
mary and secondary implant (Fig. 5c–f ).
However, there were marked differences in the dynam-
ics of PDPN and CD248 expression on fibroblasts within
both implants when observed over time (Fig. 5c). In the
primary implant, the percentage and absolute number of
fibroblasts positive for PDPN increased between day 6
and day 30 before reaching a plateau. The same pattern
was observed for CD248 expression except that the per-
centage of RASF expressing this marker reached a plat-
eau between day 18 and day 30. In the secondary
implant, containing cartilage only, the number of infil-
trating cells progressively increased over time. This was
coincident with the formation of murine vasculature (as
indicated by CD31 expression) in the primary implant at
day 6 (data not shown). However, within the secondary
implant, at early time points from day 6 onwards, almost
all RASF present within the implant expressed PDPN
and not CD248. The percentage of cells expressing
PDPN in the secondary implant decreased over time,
reaching a plateau at day 30. In complete contrast,
CD248+ cells were only detectable in the secondary
implant 18 days post-implantation and increased in
percentage up to day 60 (Fig. 5c).
Discussion
In this study we have utilized two markers (PDPN and
CD248) to distinguish between distinct populations of
SF defined by anatomical location and function. We
demonstrate that RASF have an intrinsic capacity to
self-organize into specific lining and sub-lining layers
defined by their expression of these markers in the pres-
ence of cartilage. Whilst the exact role of these two cell-
specific markers in inflammatory arthritis is not fully
known, PDPN appears to be expressed in fibroblasts
with the capacity to invade and destroy cartilage. This
observation matches previous reports suggesting that
PDPN upregulation by cancer cells and cancer-associated
fibroblasts promote metastasis [25].
CD248 and PDPN are expressed in a highly restricted
pattern in diseased tissue. PDPN expression predomin-
ately maps to the lining layer of the synovium and is
seen only on a small number of cells within the sub-
lining layer, whereas CD248 is predominantly expressed
by the sub-lining layer RASF. This differential expression
is less pronounced in normal tissue where expression of
CD248 is low and PDPN expression in the restricted to
lymphatic endothelial cells and expressed at low levels in
the lining layer. The distinction between lining and sub-
lining layer RASF is important when considering that,
during chronic inflammation, the lining layer becomes
hyperplastic and invades cartilage and bone. Synovial fi-
broblasts, but not cells of the monocyte/macrophage
lineage, have been shown to be the predominant source
of collagenase and therefore these cells are key effector
cells in joint damage [26].
When a heterogeneous population of RASF were im-
planted with human cartilage into SCID mice, we found
that RASF self-organized into lining and sub-lining
(See figure on previous page.)
Fig. 4 Cytokines stimulate differentiation of RASF towards specific fibroblast subsets in vitro. a Dual color flow cytometry of fibroblasts stimulated
with either TNF-α or TGF-β in vitro. Histograms of CD248 versus podoplanin (PDPN) expression following cytokine stimulation. Percentage of positive
cells in each gate is displayed. b The percentage of PDPN+ and CD248+ cells measured by flow cytometry in cultured RASF in response to cytokine
stimulation (TNF-α, 10 ng/ml; IL-1β, 1 ng/ml; TGF-β1, 10 ng/ml). Data are expressed as mean ± SEM of the number of PDPN- and CD248-expressing
fibroblasts expressed as a percentage of total cells at each time from N = 5 donor cell lines. Representative histograms of flow cytometric quantification
of marker expression following cytokine stimulation are shown. Arrow indicates removal of cytokine. IL interleukin, TGF transforming growth factor, TNF
tumor necrosis factor
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layers, in the absence of any other immune cells or
stimulus, suggesting that this property is an intrinsic
property of SF. Synovial fibroblasts have also been
shown to establish a lining layer structure at the interface
between matrix and fluid phase in three-dimensional
culture [27]. In agreement with our findings of self-
organization, this process is not dependent on the pres-
ence of other cell types.
Although the molecular basis for the cellular remodel-
ing of the inflamed synovium remains to be fully eluci-
dated, cadherin-11 has been shown to play a critical role
in integrating fibroblasts into the synovial lining layer
and for the development of an effective hyperplastic
synovium during inflammation [27]. Genetic deletion of
this molecule inhibits the development of a hyperplastic
synovial lining layer and abolishes inflammatory arthritis
in vivo. These studies serve to demonstrate the importance
of the fibroblast-lining layer in the pathophysiology of in-
flammatory arthritis [27].
RASF are also capable of transmigration to a second-
ary site of cartilage implantation as previously described
[6]. Following engraftment we found that RASF at the
secondary site self-organized into layers of SF indistin-
guishable from the primary site of implantation. When
we evaluated the cells involved at the early stages of en-
graftment at secondary sites, we found that the majority
of SF expressed PDPN and not CD248. It remains un-
known if the finding of high PDPN expression at early
time points and CD248 at later time points is a temporal
effect in which PDPN+ RASF migrate early and CD248+
RASF migrate later or whether this finding results from
the in situ differentiation of PDPN-expressing RASF to a
CD248-expressing fibroblast. In support of the latter, we
were able to demonstrate plasticity, based on cytokine
exposure, in the expression of these markers by fibro-
blasts in vitro. Definitive evidence for the phenotype of
migrating fibroblasts can only be determined by isolating
migrating cells in the blood stream. Unfortunately, we
were unable to identify human fibroblasts in the blood
of mice. This is probably due to the low circulating fre-
quency of these cells in the vasculature.
We found that PDPN expression correlates with an ag-
gressive fibroblast phenotype. Consistent with other
studies, PDPN expression was upregulated in the lining
layer during chronic inflammation and expression was
inducible in vitro in response to pro-inflammatory cyto-
kines. We found that the expression of PDPN and CD248
is associated with functional consequences in vivo, since
re-implantation in a SCID mouse in the presence of cartil-
age resulted in PDPN-expressing RASF invading articular
cartilage implanted at a secondary site.
RASF are known to acquire an activated phenotype
and are capable of invading cartilage (in the absence of
other stimuli) even following prolonged culture [1, 5–7,
28]. Interestingly, PDPN was only expressed by cells prox-
imal to the cartilage interface or by cells that had invaded
cartilage. This is consistent with a lining layer phenotype.
It is therefore likely that many factors play a role in deter-
mining the expression of these cell surface markers.
CD248 is transmembrane receptor whose ligands are
reported to be extracellular matrix molecules (fibronec-
tin and type I/IV collagen) [29, 30] and is widely
expressed on mesenchymal cells in the developing em-
bryo [19, 31]. However, expression is downregulated
postnatally but upregulated during tissue remodeling.
We found CD248-expressing fibroblasts predominantly
in the sub-lining tissue of the inflammatory synovium,
consistent with previous studies [32]. As expected from
their anatomical location, CD248+ SF did not invade the
implants of cartilage in vivo. It is not yet known if
CD248-expressing fibroblasts are required for the forma-
tion of a PDPN-expressing fibroblast layer capable of
invading cartilage and bone.
Conclusion
Based on the observations described in this study, we
propose that the expression of PDPN and CD248 can be
used to identify subsets of RASF defined by their anatom-
ical location in the inflamed joint and their ability to
invade and degrade articular cartilage in vivo. The differ-
ential expression of these cell surface markers on fibro-
blasts make these markers ideal candidates for selectively
targeting distinct subpopulations of SF. Better understand-
ing of the function of these molecules, and the impact of
selective deletion of cells that express them, will be critical
for the development of fibroblast-targeted treatments in
the future.
(See figure on previous page.)
Fig. 5 In vivo cartilage destruction and vascular transmigration following implantation of RASF under the kidney capsule of SCID mice. a
Representative confocal images of tissue sections of the fibro/cartilage matrix harvested 60 days following implantation showing expression of
CD248 and podoplanin (PDPN). Dashed line shows demarcation of the cartilage interface. Scale bar = 100 μm. b The percentage of cells positive
for each marker within 20 μm proximity to cartilage is displayed as the mean ± SEM for each cell marker. Time course analysis of the percentage
of total nucleated cells expressing PDPN (c) and CD248 (d) within the primary implant compared to the secondary (cartilage only) implant at 6,
12, 18, 30, and 60 days following implantation. Absolute numbers of total nucleated cells over time in sections of secondary implant are also shown
compared to the total number of those cells positive for each of these markers over time (e, f). Data are expressed as the mean ± SEM of the percentage
of cells expressing each cell marker at each time point from eight tissue sections per implant (n= 3 mice). **P< 0.001 . C cartilage fragment
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